Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study.
about
Lipoprotein(a) in cardiovascular diseasesLipoprotein(a) as a cardiovascular risk factor: current statusXanthelasmata, arcus corneae, and ischaemic vascular disease and death in general population: prospective cohort studyLipoprotein(a) should be taken much more seriouslyLipoprotein(a) and risk of myocardial infarction--genetic epidemiologic evidence of causalityLipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biologyAnalysis of 17,576 potentially functional SNPs in three case-control studies of myocardial infarction.Effect of diet-induced weight loss on lipoprotein(a) levels in obese individuals with and without type 2 diabetesLong-term statin therapy could be efficacious in reducing the lipoprotein (a) levels in patients with coronary artery disease modified by some traditional risk factors.Risk factors in the progression of subclinical atherosclerosis in women with systemic lupus erythematosus.Lipoprotein (a), an independent cardiovascular risk markerSignificant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans.Lipoprotein(a) and risk of type 2 diabetesElevated C-reactive protein associated with late- and very-late-onset schizophrenia in the general population: a prospective studyProteomic analysis of aortae from human lipoprotein(a) transgenic mice shows an early metabolic response independent of atherosclerosis.High Lipoprotein(a) Levels are Associated With Long-Term Adverse Outcomes in Acute Myocardial Infarction Patients in High Killip Classes.Thyroid hormones and thyroid hormone receptors: effects of thyromimetics on reverse cholesterol transport.Proteomics reveals the effects of sustained weight loss on the human plasma proteomeTolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.Healthy dietary interventions and lipoprotein (a) plasma levels: results from the Omni Heart Trial.Conventional and Mendelian randomization analyses suggest no association between lipoprotein(a) and early atherosclerosis: the Young Finns StudyRacial and Ethnic Variation in Lipoprotein (a) Levels among Asian Indian and Chinese Patients.Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study.Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.Apolipoprotein(a) Kringle-IV Type 2 Copy Number Variation Is Associated with Venous Thromboembolism.Lipoprotein(a) in type 2 diabetic subjects and its relationship to diabetic microvascular complicationsLipid apheresis: oxidative stress, rheology, and vasodilatation.Niacin in cardiovascular disease: recent preclinical and clinical developmentsThe Copenhagen City Heart Study (Østerbroundersøgelsen).Coronary Artery Disease Severity and Cardiovascular Biomarkers in Patients with Peripheral Artery DiseaseLipoprotein(a) and cardiovascular disease in diabetic patientsCorrelation analysis between serum lipoprotein (a) and the incidence of aortic valve sclerosis.Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humansLipoprotein(a) and apolipoprotein(a) in polycystic ovary syndrome.Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study.Lipoprotein (a) measurements for clinical application.Establishment of Relational Model of Congenital Heart Disease Markers and GO Functional Analysis of the Association between Its Serum Markers and Susceptibility Genes.A Case-Control Study of the Relationship Between SLC22A3-LPAL2-LPA Gene Cluster Polymorphism and Coronary Artery Disease in the Han Chinese Population.Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
P2860
Q21284797-A35A90DF-A2AC-40C7-9F52-D647504F14AEQ24623225-3A92272A-82B2-412B-BE08-8C3CDA65F555Q24635956-84FF8D71-1861-4E9E-8D38-C386EB0838DEQ28282665-68B10660-9F3A-41AC-84B8-247911922F0EQ28303150-86B538D5-E416-49E8-ACAA-E8F05585C549Q30242031-E5D03EA4-5E9E-4DE5-923D-21864FF42101Q33358068-EC18911C-B379-4052-9CB3-8207BBEB8B0DQ33654017-04597445-16F9-409A-851D-E85601003AB3Q33780263-A68AD326-31AA-46B6-98C3-54905FD724B9Q33800900-34D74FC6-F3C6-4490-8DA6-F349F3C9BA7BQ33801207-952AD839-1371-4831-BC87-EC9A9656B564Q33892999-D8189A7B-BA30-411E-A575-D905D2FADB77Q34029711-09017BC6-44D4-4C01-B4AD-2DC95DEEBA9FQ34048554-0F80D649-87DA-44FE-A686-E66C27954FF0Q34140556-A50E4D75-B69B-4CF0-9D70-DE160DB37EB4Q34297896-FEF11B56-9CF7-433D-8F27-5F8BD90408E6Q34428756-FA311250-1591-4443-B9C4-50DEB1144590Q34547857-2C27894B-F278-4572-A3C0-0CED25A5211AQ34571030-B5E99B29-D6B8-4715-A480-691543BC3D2BQ34704070-F85D016C-ED77-4625-8256-C79D867AFA5EQ35020898-7A674532-F61B-4D09-A091-CC39D92FE187Q35024656-7AAFB6B5-141F-473C-ACB1-EABADF3D10DBQ35558075-4FED32F8-07E2-46F3-98F2-C52C99982059Q35592510-32618C1D-C06F-4EE1-8B87-38D22F6FFB41Q35737842-0BBD0CE4-0E8A-4060-BCDA-6211E3ACC544Q35930428-12FC426F-806D-430E-8936-DDEDC6CB3981Q35988129-F63B25EC-3EDB-46FE-AF39-18D92615FB2CQ36028615-8E14E6E1-051A-4212-8DC2-E1BA8F7287C1Q36084389-59CDD0D7-1152-426A-8301-70A1022F4437Q36221801-30F63E05-764F-4DFA-9E32-D3FFD237FD9BQ36307793-85FE05E3-82BF-4694-9380-C5232F9ECF31Q36369444-8820AF2E-64A8-4EF3-97B8-61B8DC2F0434Q36412236-77508EC9-2B85-42D7-A0BA-6F76A065EB58Q36617508-5B147FC6-2FDD-47C6-A7F8-D70E6C8EF945Q36653816-6974E4A5-31FB-4FE2-BDBF-769C7AF2C94FQ36731797-6847D152-3ADE-4EDC-B0B9-9078130EEBDAQ36731801-88176FD3-4CAC-4151-A986-25A043D0B89BQ36741300-2F130C00-E276-4A61-9351-687052C99F53Q37231203-13E22A14-3922-483E-A42B-6DF6E8D36D15Q37278608-60D31CA1-26EA-42F8-A4EB-22BBBA495849
P2860
Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Extreme lipoprotein
@nl
Extreme lipoprotein(a) levels ...... e Copenhagen City Heart Study.
@ast
Extreme lipoprotein(a) levels ...... e Copenhagen City Heart Study.
@en
type
label
Extreme lipoprotein
@nl
Extreme lipoprotein(a) levels ...... e Copenhagen City Heart Study.
@ast
Extreme lipoprotein(a) levels ...... e Copenhagen City Heart Study.
@en
prefLabel
Extreme lipoprotein
@nl
Extreme lipoprotein(a) levels ...... e Copenhagen City Heart Study.
@ast
Extreme lipoprotein(a) levels ...... e Copenhagen City Heart Study.
@en
P921
P1433
P1476
Extreme lipoprotein(a) levels ...... e Copenhagen City Heart Study.
@en
P2093
Marianne Benn
Pia R Kamstrup
P304
P356
10.1161/CIRCULATIONAHA.107.715698
P407
P577
2007-12-17T00:00:00Z